DTC Report: DTC Unbound

DTC pharma advertising works—ask anyone. But over the years, its effectiveness has been blunted by FDA requirements that, marketers claim, befog rather than clarify. Larry ...

Engaging HCPs: Rep and a Hard Place

Technology has, quite clearly, transformed the role of the sales rep. But at the same time, predictions that the rep would go the way of ...

Headliner: Dexcom device executive presses connectivity

"Some people wake up in the middle of the night worrying about business," Kevin Sayer says. But when he wakes up he can't sleep because ...

Therapeutic Focus: Respiratory

The respiratory field, in which several launches are under way, is branching out, from long-time dominant fixed-dose combinations to a therapeutic arsenal that includes biologics ...

Rare Diseases: Target Practice

The orphan-drug market was flying high before President Obama announced plans to devote $215 million to the funding of a Precision Medicine Initiative. Imagine the ...

Latest

Teva concealed kickbacks in speaker program, former reps allege

Teva concealed kickbacks in speaker program, former reps allege

Two former Teva sales representatives say the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

FDA finalizes opioid guidance

Opioids lacking abuse-foiling technology will remain available.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Read the complete April 2015 Digital Edition

Read the complete April 2015 Digital Edition

Click the above link to access the Digital Edition of the April 2015 issue of MM&M, with all text, charts and pictures.

Washington Insider: James G. Dickinson

Washington Insider: James G. Dickinson

The FDA has to respect First Amendment limitations regulating scientific communication

Who Will Pay the Piper?

Who Will Pay the Piper?

Robbing pharma to pay Senator Pothole will not encourage innovation

SkillSets: Omnicare Inc.

SkillSets: Omnicare Inc.

A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. This month: Rare Diseases

Viewpoint: The Odd Couple—Storytellers and Data Miners

Viewpoint: The Odd Couple—Storytellers and Data Miners

Storytellers can both build meaningful story lines out of trend lines and construct rationales from ratios

Private View: John Kemble

Private View: John Kemble

Partner Forum: MLR is important. What drives it?

Sorting out competing priorities is one way to expedite medical-legal review. What should drive work flow—great creative for the brand or need to mitigate risk (compliance, legal, medical, regulatory, brand image)?

Game-Changing Companies in 2015

Game-Changing Companies in 2015

MM&M's showcase of healthcare marketing, communications, tech, media and research companies that are helping to shape the future of the industry

Agency Spotlight


 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters